Precision oncology approaches include inhibition/blockade of various receptor tyrosine kinases [20,21,22], specific targeting of KRAS proto-oncogene (KRAS) mutations [23], synthetic lethal approaches to target homologous recombination deficient (HRD) cancers with poly (ADP-ribose) polymerase (PARP) inhibitors [24], biomarker-driven enhancement of response rates to immune checkpoint blockade [25,26,27], and the generation of chimeric antigen receptor T-cell (CAR-T) therapies [28]. The gene discussed is KRAS; the disease is cancer.